and Cato BioVentures have struck a business development deal with VistaGen Therapeutics.
Under the contract, VistaGen, which is based in Burlingame CA, gets exclusive rights of first negotiation for all central nervous system (CNS) product opportunities that Cato and Cato BioVentures identify or acquire.
Financial terms were not disclosed.
Cato BioVentures is the venture capital arm of Cato, an RTP-based contract research organization.
"VistaGen's CNS focus and leading embryonic stem cell-based drug discovery and development technology provide an ideal leverage opportunity for our expanding CNS product acquisition and investment activities," said Shawn Singh, managing principal of Cato BioVentures who also is a member of VistaGen's board of directors. "VistaGen's management team is strong, its core technology is broadly applicable and its technical expertise is deep."
Copyright 2024 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
